February 10, 2022 -- Ventus Therapeutics closed $140 million in series C financing. The funding will allow the company to scale its Resolve platform to address targets previously considered undruggable and enhance its performance by automating processes, expanding machine-learning capabilities, and constructing larger proprietary virtual libraries.
Additionally, the company plans to target key modulators in the innate immune system, including nucleotide-binding oligomerization, leucine-rich repeat, and pyrin domain-containing protein 3 (NLRP3) and cyclic guanosine monophosphate (GMP)-adenosine monophosphate synthase (cGAS) that have been extensively implicated in human disease, Ventus said.
Ventus' lead drug program, Vent-01, is a peripherally restricted, small molecule inhibitor compound targeting NLRP3. NLRP3 is a key mediator of proinflammatory cytokines IL-1b and IL-18. The company has a second drug program, which is a brain-penetrating NLRP3 inhibitor. Ventus' third drug program targets cGAS, a key regulator of the cGAS/stimulator of interferon genes pathway.
Ventus Therapeutics is a biopharmaceutical company using structural biology and computational tools to identify and develop small molecule therapeutics across a broad range of disease indications, with an initial focus on immunology, inflammation, and neurology.
The round was co-led by SoftBank Vision Fund 2 and RA Capital Management, with participation from various other investors.
Copyright © 2022 scienceboard.net
Member Rewards
Earn points for contributing to market research. Redeem your points for merchandise, travel, or even to help your favorite charity.
Research Topics
Interact with an engaged, global community of your peers who come together to discuss their work and opportunities.
Conferences
Connect
